Altimmune to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Altimmune (NASDAQ:ALT), a late clinical-stage biopharmaceutical company focused on peptide-based therapeutics for liver and cardiometabolic diseases, has announced its participation in three upcoming investor conferences in September 2025.
The company will attend the Wells Fargo Healthcare Conference in Boston on September 5 for one-on-one meetings, the H.C. Wainwright Global Investment Conference in New York on September 9 with a fireside chat at 8:30 a.m. ET, and the Morgan Stanley Global Healthcare Conference in New York on September 10 with a fireside chat at 7:45 a.m. ET. The fireside chat sessions will be available via webcast on Altimmune's website.
Positive
- None.
Negative
- None.
News Market Reaction 8 Alerts
On the day this news was published, ALT gained 1.47%, reflecting a mild positive market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $5M to the company's valuation, bringing the market cap to $327M at that time. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences:
- Wells Fargo Healthcare Conference in Boston, MA
Friday, September 5, 2025
One-on-one meetings only
- H.C. Wainwright Global Investment Conference in New York, NY
Tuesday, September 9, 2025
Fireside chat at 8:30 a.m. Eastern Time
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
- Morgan Stanley Global Healthcare Conference in New York, NY
Wednesday, September 10, 2025
Fireside chat at 7:45 a.m. Eastern Time
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD) and obesity. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Phone: 619-849-5383
jake.robison@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Altimmune (ALT) presenting at the H.C. Wainwright Global Investment Conference 2025?
Where can I watch Altimmune's (ALT) presentations at the September 2025 investor conferences?
What type of company is Altimmune (ALT)?
Which investor conferences is Altimmune (ALT) attending in September 2025?
